178 related articles for article (PubMed ID: 18519765)
1. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
[TBL] [Abstract][Full Text] [Related]
2. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility.
Teixeira AL; Ribeiro R; Morais A; Lobo F; Fraga A; Pina F; Calais-da-Silva FM; Calais-da-Silva FE; Medeiros R
Pharmacogenomics J; 2009 Oct; 9(5):341-6. PubMed ID: 19488063
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease.
Araújo AP; Ribeiro R; Pinto D; Pereira D; Sousa B; Mauricio J; Lopes C; Medeiros R
DNA Cell Biol; 2009 May; 28(5):265-9. PubMed ID: 19388850
[TBL] [Abstract][Full Text] [Related]
5. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration.
Fraga A; Ribeiro R; Príncipe P; Lobato C; Pina F; Maurício J; Monteiro C; Sousa H; Calais da Silva F; Lopes C; Medeiros R
Eur J Cancer; 2014 Jan; 50(2):359-65. PubMed ID: 24090974
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
[TBL] [Abstract][Full Text] [Related]
7. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer.
Vishnoi M; Pandey SN; Modi DR; Kumar A; Mittal B
Hum Immunol; 2008 Jun; 69(6):360-7. PubMed ID: 18571008
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene.
Araújo AP; Ribeiro R; Pereira D; Pinto D; Sousa B; Catarino R; Medeiros R
Exp Biol Med (Maywood); 2009 Mar; 234(3):241-5. PubMed ID: 19144868
[TBL] [Abstract][Full Text] [Related]
9. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
Hayes VM; Severi G; Eggleton SA; Padilla EJ; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):993-6. PubMed ID: 15824176
[TBL] [Abstract][Full Text] [Related]
10. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
11. Association between functional EGF+61 polymorphism and glioma risk.
Costa BM; Ferreira P; Costa S; Canedo P; Oliveira P; Silva A; Pardal F; Suriano G; Machado JC; Lopes JM; Reis RM
Clin Cancer Res; 2007 May; 13(9):2621-6. PubMed ID: 17473192
[TBL] [Abstract][Full Text] [Related]
12. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan.
Huang SP; Yu CC; Liu CC; Wu TT; Huang CH; Wu MT
Urol Int; 2008; 81(1):36-40. PubMed ID: 18645269
[TBL] [Abstract][Full Text] [Related]
13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
14. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.
Langsenlehner T; Langsenlehner U; Renner W; Kapp KS; Krippl P; Hofmann G; Clar H; Pummer K; Mayer R
Prostate; 2008 Feb; 68(3):264-8. PubMed ID: 18163425
[TBL] [Abstract][Full Text] [Related]
15. The A61G EGF polymorphism is associated with development of extraaxial nervous system tumors but not with overall survival.
Almeida LO; Custódio AC; Santos MJ; Almeida JR; Clara CA; Pinto GR; Rey JA; Casartelli C
Cancer Genet Cytogenet; 2010 Apr; 198(1):15-21. PubMed ID: 20303009
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
18. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer.
Hamai Y; Matsumura S; Matsusaki K; Kitadai Y; Yoshida K; Yamaguchi Y; Imai K; Nakachi K; Toge T; Yasui W
Pathobiology; 2005; 72(3):133-8. PubMed ID: 15860930
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population.
Lim YJ; Kim JW; Song JY; Hong MS; Jin SY; Yoon SH; Park HJ; Choe BK; Lee JJ; Yim SV; Hong SI; Baik HH; Ha E; Park YH
Neurosci Lett; 2005 Feb; 374(3):157-60. PubMed ID: 15663953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
